Log in
Enquire now
‌

US Patent 11787803 Tetrahydro-imidazo quinoline compositions as CBP/P300 inhibitors

Patent 11787803 was granted and assigned to FORMA Therapeutics on October, 2023 by the United States Patent and Trademark Office.

OverviewStructured DataIssuesContributors
Is a
Patent
Patent
Current Assignee
FORMA Therapeutics
FORMA Therapeutics
Date Filed
February 10, 2022
Date of Patent
October 17, 2023
Patent Applicant
FORMA Therapeutics
FORMA Therapeutics
Patent Application Number
17669135
Patent Citations
‌
US Patent 9211333 Anti-cancer agents synthesized based on miliusane compounds
‌
US Patent 7101869 2,4-diaminopyrimidine compounds useful as immunosuppressants
‌
US Patent 7709489 Imidazoquinoline derivatives as adenosine A3 receptor ligands
‌
US Patent 9975896 Inhibitors of transcription factors and uses thereof
Patent Inventor Names
Anna Ericsson
Shawn E. R. Schiller
Hongbin Li
Angela V. West
Torsten Herbertz
Jennifer R. Downing
Steven Mischke
Bradford Graves
Patent Jurisdiction
United States Patent and Trademark Office
United States Patent and Trademark Office
Patent Number
11787803
Patent Primary Examiner
‌
John M Mauro
CPC Code
‌
A61P 35/00
‌
C07D 519/00
‌
C07D 471/04

Find more entities like US Patent 11787803 Tetrahydro-imidazo quinoline compositions as CBP/P300 inhibitors

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
Open Query Tool
Access by API
Golden Query Tool
Golden logo
By using this site, you agree to our Terms of Service.